• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

A Game-changer in the Fight against Melanoma

  Pembrolizumab
  Pembrolizumab
  Pembrolizumab
 

Top: White blood cells attempt to attack a deadly melanoma cancer tumor but are blocked by a protein that rises up from the cancer cell like a shield. Second: Pembrolizumab blocks the protein and breaks down the protective shield. Bottom: After treatment with pembrolizumab, the immune system is able to resume its attack by the white blood cells, shrinking the tumors.
Graphics: Courtesy of UCLA Jonsson Comprehensive Cancer Center

The U.S. Food and Drug Administration (FDA) approved a new immunotherapy drug to treat advanced melanoma, signaling a paradigm shift in the way the deadly skin cancer is treated. UCLA led the international team of researchers testing the drug, pembrolizumab, in the largest Phase 1 study ever conducted in the history of oncology.

Pembrolizumab (Keytruda) was tested on more than 600 patients who had melanoma that had spread throughout their bodies. Because so many of the patients in the early testing showed significant long-lasting responses, the study was continued, and the FDA granted the drug “breakthrough therapy” status, allowing it to be fast-tracked for approval.

“This drug is a game-changer, a very-signifi cant advance in the treatment of melanoma,” says principal investigator Antoni Ribas, MD (FEL ’98, ’01), PhD, assistant director for clinical programs in the UCLA Human Gene Medicine Program. “For patients who have not responded to prior therapies, this drug now provides a very real chance to shrink their tumors and the hope of a lasting response to treatment.” Pembrolizumab, formerly known as MK-3475, is an antibody that targets a protein called PD-1 that is expressed by immune cells. Th e protein applies the brakes to the immune system, keeping its T cells from recognizing and attacking cancer cells and hindering therapeutic attempts to fight the disease. Pembrolizumab, in eff ect, cuts the brake lines, freeing up the immune system to attack the cancer.

“We have long believed that harnessing the power of our own immune systems would dramatically alter cancer treatment,” says Judith Gasson, PhD, senior associate dean for research at the David Geffen School of Medicine at UCLA and director of UCLA’s Jonsson Comprehensive Cancer Center. “Based upon work conducted over the past two decades, we are beginning to see the clinical benefi ts of this research in some of the most-challenging cancers.”

Generally, about one-in-10 patients responded to previous immunotherapy drugs. Some of those who responded, however, exhibited long-lived benefits, which sustained scientists’ interest in the method as an effective mechanism to fight cancer. The response and duration rates for pembrolizumab were much greater than for previous drugs, Dr. Ribas says. In the new study, 72 percent of patients responded to the drug — their tumors shrank to some degree. Overall, 34 percent of patients showed an objective response, meaning that their tumors shrank by more than 30 percent and did not re-grow.

Dr. Ribas said pembrolizumab has the potential to be used to treat other cancers that the immune system can recognize, including cancers of the lung, bladder, head and neck.

To hear melanoma survivors speak about their experiences with pembrolizumab, go to: uclahealth.org/tomstutz and uclahealth.org/kathythomas.

 


Previous
Surgery through the Lens of Google Glass
Next
Ferric Factor


YOU ARE VIEWING

Fall 2014

Fall 2014
E-Brochure
Printable PDF
IN THIS ISSUE
  • Toward a Bright Tomorrow
  • Surgery through the Lens of Google Glass
  • A Game-changer in the Fight against Melanoma
  • Ferric Factor
  • A Double Dose of Promising Lung-cancer Findings
  • The Healing Heart
  • Gene May Offer Target to Combat Parkinson’s Disease
  • The True Healthcare Costs of Undocumented Immigrants
  • Lost in Translation
  • Depression Increases Risk for Diabetic Seniors
  • Redesigning the Well-child Checkup
  • Change Agent
  • To Heal the Human Instrument
  • Finding the Right Path
  • At the End of Too-few Days
  • Front-line Physician
  • Awards/Honors
  • In Memoriam
  • Promoting Exchange to Encourage Change
  • 2014 Alumnus of the Year
  • In His Own Words: Kevin Teehee, MD ’97
  • Postcard from Mozambique
  • UCLA Bestows Highest Honor on Distinguished Philanthropists
  • UCLA Health Sciences Honors Robert Draine
  • Music Creates a Personal Evening
  • Art and Science Take Flight at the Space Shuttle Pavilion
  • Celebrity Poker Event Benefits Center for Duchenne Muscular Dystrophy at UCLA
  • Visionary Force Behind UCLA Pancreatic-Cancer Research
  • Chairs of Distinction
  • In Memoriam
  • Gifts
  • From Patient to Physician: A Personal Journey
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth